menu
    • menu

    Company profile for LIB Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulation as quickly and smoothly as possible. This has enabled LIB to develop and optimize the manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology...
    LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulation as quickly and smoothly as possible. This has enabled LIB to develop and optimize the manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology, phase 1, phase 2 dose selection, a 52-week phase 2b trials, and initiate and enroll 7 large global phase 3 trials in under 6 years.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LIB TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5375 Medpace Way Cincinnati, OH 45227-1543
    Telephone
    Telephone
    +1 8003452032
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.libtherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LIB Therapeutics Presents LEROCHOL Data ACC 2026
    LIB Therapeutics Presents LEROCHOL Data ACC 2026

    30 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260330690384/en/LIB-Therapeutics-Announces-Results-from-Presentations-on-LEROCHOL-at-2026-American-College-of-Cardiology-meeting-in-New-Orleans-March-28-29-2026

    BUSINESSWIRE
    30 Mar 2026
    Share Share
    FDA Approves LIB Therapeutics' LEROCHOL For High LDL Cholesterol
    FDA Approves LIB Therapeutics' LEROCHOL For High LDL Cholesterol

    15 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251215907781/en/U.S.-Food-and-Drug-Administration-Approves-LIB-Therapeutics-LEROCHOL-lerodalcibep-liga-for-Adults-with-Elevated-LDL-Cholesterol

    BUSINESSWIRE
    15 Dec 2025
    Share Share
    Lib ,’s Biologics Lerochol Receives Approval in US
    Lib ,’s Biologics Lerochol Receives Approval in US

    12 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761427

    FDA
    12 Dec 2025
    Share Share
    LIB Therapeutics Unveils Late-Breaking Data At 2025 AHA
    LIB Therapeutics Unveils Late-Breaking Data At 2025 AHA

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110544029/en/LIB-Therapeutics-Announces-Results-from-Late-Breaking-Science-Presentation-at-2025-American-Heart-Association-Meeting-in-New-Orleans-November-9-2025

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    LIB Therapeutics Reveals Results at 2025 Atherosclerosis Society
    LIB Therapeutics Reveals Results at 2025 Atherosclerosis Society

    06 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250506664509/en/LIB-Therapeutics-Announces-Key-Results-from-Presentations-at-2025-European-Atherosclerosis-Society-Meeting-in-Glasgow-May-5-6

    BUSINESSWIRE
    06 May 2025
    Share Share
    Lerodalcibep May Help Patients Needing More LDL-C Reduction
    Lerodalcibep May Help Patients Needing More LDL-C Reduction

    04 Mar 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/lerodalcibep-can-be-a-treatment-option-for-patients-requiring-additional-ldl-c-reduction-globaldata/

    EXPRESSPHARMA
    04 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search